EVOK - イヴォ―ク・ファ―マ (Evoke Pharma Inc.) イヴォ―ク・ファ―マ

 EVOKのチャート


 EVOKの企業情報

symbol EVOK
会社名 Evoke Pharma Inc (イヴォ―ク・ファ―マ)
分野(sector) Health Care   ヘルスケア
産業(industry) Major Pharmaceuticals  
業種 医薬品   医療関連(Health Care)
概要 事業概要 イヴォーク・ファーマ(Evoke Pharma Inc.)は特殊製薬会社である。同社は主に胃腸(GI)の障害と疾患を治療する薬剤の開発に取り組む。同社は真性糖尿病を持つ女性の急性・再発糖尿病性胃不全麻痺に関連する症状の軽減向けのメトクロプラミド鼻腔用スプレーである「EVK-001」を開発している。同社の主要候補製品「EVK-001」は後期臨床試験にある。「EVK-001」は鼻腔内投与を通じてメトクロプラミドの全身的送達を提供するように設計された製剤である。胃不全麻痺は機械的閉塞がない場合の胃内容排出遅延という疾患である。胃不全麻痺は食品が正常より長い時間胃の中に残ることをもたらし、多様な症状を生じる。   イヴォ―ク・ファ―マは、米国の医薬品会社。主に、胃腸疾患の治療薬の研究開発に従事。中でも、糖尿病性胃不全麻痺の治療用メトクロプラミド鼻腔内投与システム「EVK-001」の商品化を目指し、同薬の臨床試験に焦点を当てている。本社は、カリフォルニア州ソラナ・ビ―チ。   
本社所在地 420 Stevens Avenue Suite 370 Solana Beach CA 92075 USA
代表者氏名 Cam L. Garner カム・L・ガーナー
代表者役職名 Chairman and Co Founder
電話番号 +1 858-345-1494
設立年月日 39083
市場名 NASDAQ Small Cap
ipoyear 2013年
従業員数
url www.evokepharma.com
nasdaq_url https://www.nasdaq.com/symbol/evok
adr_tso
EBITDA EBITDA(百万ドル) -11.08459
終値(lastsale) 2.58
時価総額(marketcap) 43598553.12
時価総額 時価総額(百万ドル) 45.28842
売上高 売上高(百万ドル) 0.00000
企業価値(EV) 企業価値(EV)(百万ドル) 38.75734
当期純利益 当期純利益(百万ドル) -9.83748
決算概要 決算概要 BRIEF: For the six months ended 30 June 2018 Evoke Pharma Inc revenues was not reported. Net loss decreased 36% to $4.3M. Lower net loss reflects FV Adjustments of Financial Investments. increase from $1.8M (expense) to $436K (income). Basic Earnings per Share excluding Extraordinary Items increased from -$0.48 to -$0.27.

 EVOKのテクニカル分析


 EVOKのニュース

   Why ContraFect, Evoke, Altimmune, Novavax Are Moving Friday  2021/03/12 16:32:53 Benzinga
Among the health care stock movers Friday are ContraFect Corporation (NASDAQ: CFRX ), Evoke Pharma, Inc. (NASDAQ: EVOK ), Altimmune, Inc. (NASDAQ: ALT ) and Novavax, Inc. (NASDAQ: NVAX ). Here's why the stocks are moving. ContraFect Bags BARDA Funding: ContraFect, a biotech focused on developing treatments for antibiotic-resistant infections, said late Thursday BARDA has awarded $86.8 million in funding for supporting the pivotal late-stage study of exebacase as a treatment option for blood stream infection as well as infection of the heart's inner lining caused by the staphylococcus aureus bacteria. If the Phase 3 data proves to be positive, BARDA could extend additional financial assistance upon achievement of key milestones to advance the investigational asset through FDA approval and completion of post-approval commitments. Evoke Plunges On Gimoti Disappointment: Evoke was pulling back sharply following the … Full story available on Benzinga.com
   92 Biggest Movers From Yesterday  2021/02/10 10:16:46 Benzinga
Gainers Applied UV, Inc. (NASDAQ: AUVI ) shares surged 280.5% to close at $19.71 on Tuesday. The company earlier announced closing on acquisition of Akida Holdings for 1.375 million shares and $901,274.96 in cash. Cloopen Group Holding Ltd. ADR (NYSE: RAAS ) gained 200% to close at $48.00 after the company priced 20 million shares at $16 per share in its upsized initial public offering (IPO) to rake $320 million in offering proceeds. KalVista Pharmaceuticals, Inc. (NASDAQ: KALV ) shares jumped 114.6% to close at $33.50 as the company announced positive topline data from a Phase 2 clinical trial demonstrating statistically and clinically significant efficacy of KVD900 as an oral on-demand treatment for hereditary angioedema attacks. Comstock Holding Companies, Inc. (NASDAQ: CHCI ) surged 98.2% to close at $8.38 after climbing over 18% on Monday. PDS Biotechnology Corporation (NASDAQ: PDSB ) gained 53.4% to close at $6.81. PDS Biotech, last week, reported preliminary efficacy achievement in Phase 2 combo trial of PDS0101 led by National Cancer Institute.
   Evoke Pharma Announces Proposed Public Offering of Common Stock | MarketScreener  2021/01/13 21:02:05 MarketScreener
SOLANA BEACH, Calif., Jan. 13, 2021 -- Evoke Pharma, Inc. , a specialty pharmaceutical company focused on treatments for gastrointestinal disorders and diseases, today announced that it… | January 13, 2021
   Insider Selling: Evoke Pharma, Inc. (NASDAQ:EVOK) CEO Sells $70,424.76 in Stock  2020/12/15 10:58:48 Watchlist News
Evoke Pharma, Inc. (NASDAQ:EVOK) CEO David A. Gonyer sold 23,954 shares of the firm’s stock in a transaction on Monday, December 14th. The stock was sold at an average price of $2.94, for a total transaction of $70,424.76. Following the completion of the sale, the chief executive officer now directly owns 363,736 shares in the […]
   Evoke Pharma Reports Third Quarter 2020 Financial Results  2020/11/10 13:30:00 GlobeNewswire
Gimoti™ commercial launch underway SOLANA BEACH, Calif., Nov. 10, 2020 (GLOBE NEWSWIRE) -- Evoke Pharma, Inc. (NASDAQ: EVOK), a specialty pharmaceutical…
   Why ContraFect, Evoke, Altimmune, Novavax Are Moving Friday  2021/03/12 16:32:53 Benzinga
Among the health care stock movers Friday are ContraFect Corporation (NASDAQ: CFRX ), Evoke Pharma, Inc. (NASDAQ: EVOK ), Altimmune, Inc. (NASDAQ: ALT ) and Novavax, Inc. (NASDAQ: NVAX ). Here's why the stocks are moving. ContraFect Bags BARDA Funding: ContraFect, a biotech focused on developing treatments for antibiotic-resistant infections, said late Thursday BARDA has awarded $86.8 million in funding for supporting the pivotal late-stage study of exebacase as a treatment option for blood stream infection as well as infection of the heart's inner lining caused by the staphylococcus aureus bacteria. If the Phase 3 data proves to be positive, BARDA could extend additional financial assistance upon achievement of key milestones to advance the investigational asset through FDA approval and completion of post-approval commitments. Evoke Plunges On Gimoti Disappointment: Evoke was pulling back sharply following the … Full story available on Benzinga.com
   92 Biggest Movers From Yesterday  2021/02/10 10:16:46 Benzinga
Gainers Applied UV, Inc. (NASDAQ: AUVI ) shares surged 280.5% to close at $19.71 on Tuesday. The company earlier announced closing on acquisition of Akida Holdings for 1.375 million shares and $901,274.96 in cash. Cloopen Group Holding Ltd. ADR (NYSE: RAAS ) gained 200% to close at $48.00 after the company priced 20 million shares at $16 per share in its upsized initial public offering (IPO) to rake $320 million in offering proceeds. KalVista Pharmaceuticals, Inc. (NASDAQ: KALV ) shares jumped 114.6% to close at $33.50 as the company announced positive topline data from a Phase 2 clinical trial demonstrating statistically and clinically significant efficacy of KVD900 as an oral on-demand treatment for hereditary angioedema attacks. Comstock Holding Companies, Inc. (NASDAQ: CHCI ) surged 98.2% to close at $8.38 after climbing over 18% on Monday. PDS Biotechnology Corporation (NASDAQ: PDSB ) gained 53.4% to close at $6.81. PDS Biotech, last week, reported preliminary efficacy achievement in Phase 2 combo trial of PDS0101 led by National Cancer Institute.
   Evoke Pharma Announces Proposed Public Offering of Common Stock | MarketScreener  2021/01/13 21:02:05 MarketScreener
SOLANA BEACH, Calif., Jan. 13, 2021 -- Evoke Pharma, Inc. , a specialty pharmaceutical company focused on treatments for gastrointestinal disorders and diseases, today announced that it… | January 13, 2021
   Insider Selling: Evoke Pharma, Inc. (NASDAQ:EVOK) CEO Sells $70,424.76 in Stock  2020/12/15 10:58:48 Watchlist News
Evoke Pharma, Inc. (NASDAQ:EVOK) CEO David A. Gonyer sold 23,954 shares of the firm’s stock in a transaction on Monday, December 14th. The stock was sold at an average price of $2.94, for a total transaction of $70,424.76. Following the completion of the sale, the chief executive officer now directly owns 363,736 shares in the […]
   Evoke Pharma Reports Third Quarter 2020 Financial Results  2020/11/10 13:30:00 GlobeNewswire
Gimoti™ commercial launch underway SOLANA BEACH, Calif., Nov. 10, 2020 (GLOBE NEWSWIRE) -- Evoke Pharma, Inc. (NASDAQ: EVOK), a specialty pharmaceutical…
   Evoke Pharma Announces Proposed Public Offering of Common Stock | MarketScreener  2021/01/13 21:02:05 MarketScreener
SOLANA BEACH, Calif., Jan. 13, 2021 -- Evoke Pharma, Inc. , a specialty pharmaceutical company focused on treatments for gastrointestinal disorders and diseases, today announced that it… | January 13, 2021
   Insider Selling: Evoke Pharma, Inc. (NASDAQ:EVOK) CEO Sells $70,424.76 in Stock  2020/12/15 10:58:48 Watchlist News
Evoke Pharma, Inc. (NASDAQ:EVOK) CEO David A. Gonyer sold 23,954 shares of the firm’s stock in a transaction on Monday, December 14th. The stock was sold at an average price of $2.94, for a total transaction of $70,424.76. Following the completion of the sale, the chief executive officer now directly owns 363,736 shares in the […]
   Evoke Pharma Reports Third Quarter 2020 Financial Results  2020/11/10 13:30:00 GlobeNewswire
Gimoti™ commercial launch underway SOLANA BEACH, Calif., Nov. 10, 2020 (GLOBE NEWSWIRE) -- Evoke Pharma, Inc. (NASDAQ: EVOK), a specialty pharmaceutical…
   The Daily Biotech Pulse: India Globalization Gets Nod For Alzheimer's Trial, Moderna's Vaccine Deal With US, Cellular Biomedicine To Go Private  2020/08/12 11:08:59 Benzinga
Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Aug. 11) Allovir Inc (NASDAQ: ALVR ) Erytech Pharma SA (NASDAQ: ERYP ) Eyenovia Inc (NASDAQ: EYEN ) (announced an exclusive collaboration and licensing agreement for MicroLine and MicroPine in Greater China and South Korea) Evoke Pharma Inc (NASDAQ: EVOK ) Fortress Biotech (NASDAQ: FBIO )(reacted to its second-quarter results) GENMAB A/S/S ADR (NASDAQ: GMAB ) Inari Medical Inc (NASDAQ: NARI ) iTeos Therapeutics Inc (NASDAQ: ITOS ) Kura Oncology Inc (NASDAQ: KURA ) OncoSec Medical Inc (NASDAQ: ONCS ) Orthopediatrics Corp (NASDAQ: KIDS ) Pacira Biosciences Inc (NASDAQ: PCRX ) Rocket Pharmaceuticals Inc (NASDAQ: RCKT ) Silk Road Medical Inc (NASDAQ: SILK ) Trevi Therapeutics Inc (NASDAQ: TRVI ) Down In The Dumps (Biotech Stocks Hitting 52-week Lows Aug. 11) Burning Rock Biotech Ltd (NASDAQ: BNR )(announced its second-quarter results) Homology Medicines Inc (NASDAQ: FIXX )(reacted to its second-quarter results) Legend Biotech Corp (NASDAQ: LEGN ) Nurix Therapeutics Inc (NASDAQ: NRIX ) Stocks In Focus Moderna Clinches Deal With U.S.
   Evoke Pharma Reports Second Quarter 2020 Financial Results  2020/08/06 12:30:00 GlobeNewswire
Preparing for commercial launch of GIMOTI™ in 4Q 2020

 関連キーワード  (医薬品 米国株 イヴォ―ク・ファ―マ EVOK Evoke Pharma Inc.)

 twitter  (公式ツイッターやCEOツイッターなど)